



Adherium has commenced production and market release of the new, next generation GSK pMDI sensors

Melbourne, Australia – 9 October 2023: Adherium Limited (“Adherium” or “the Company”; ASX: ADR), a leader in respiratory eHealth, remote patient monitoring and data management solutions, is pleased to announce that it has commenced production and market release of the new, next generation Hailie[®] sensors with physiological parameters connecting GlaxoSmithKline (GSK) Ventolin[®], Advair[®]/Flixotide[®] and Flovent[®]/Seretide[®] inhalers for monitoring Asthma and Chronic Obstructive Pulmonary Disease (COPD).

Mr Rick Legleiter, Adherium Chief Executive Officer, commented, “Purchase orders are in house with a fast growing pipeline for our sensors with expanded data capabilities. This latest market release expands the portfolio by adding more inhalers covered with physiological parameter capabilities. I am excited for patients and for commercial focus with our business partners.”

Preventable hospitalisations cost the US health system alone US\$34 billion annually. The Hailie platform’s physiological parameters offer enhanced monitoring services for patients with severe, uncontrolled, and difficult to treat respiratory diseases, providing opportunities to improve patient management, increase responsiveness to exacerbations and ultimately reduce hospitalisations. The market adoption of digital health innovations in the US is encouraged by the Centers for Medicare & Medicaid Services (CMS) who provide reimbursement for remote patient monitoring.

Hailie enables doctors to bill for long-term, remote patient management under established US reimbursement codes. Adherium gets paid for sensor sales and by receiving monthly, per patient fees for generating and transmitting respiratory data.

"Ineffective usage and adherence tragically limit up to 90% of patients from receiving the full benefit of their transformative inhaled medications. With our groundbreaking Hailie sensors, we're championing proactive self-care, pioneering data-driven remote monitoring, and propelling enhanced outcomes at unparalleled lower cost, said Francis White, Adherium’s VP Global Business Development.



Supported by US 510(k), Australia TGA and UK MHRA market clearances, this market release expands Adherium's Hailie sensor portfolio in the US, as well as across other regions including Australia, and the UK. Adherium offers the only 510(k) cleared sensor technology on the market today with respiratory flow data, in addition to the traditional adherence measurement at the time of medication use, for Asthma and COPD inhaler medications.

These new sensors continue Adherium's focus on physiological data capture including inhalation duration and peak inhalation flow, alongside traditional Asthma/COPD medication adherence monitoring. This is an important step in enabling Asthma and COPD sufferers to receive increased support and assisting them with their medication usage and disease management, while at the same time enhancing our remote patient monitoring capability via the Adherium Hailie Portal.

-ENDS-

Enquiries:
Rick Legleiter
CEO
Adherium Limited
investors@adherium.com

About Adherium (ASX: ADR)

Adherium Limited (ASX: ADR) is a digital health company providing solutions for improving patient treatment with remote monitoring and data solutions. Its Hailie® system is transforming management of chronic respiratory conditions, especially asthma and chronic obstructive pulmonary disease. Hailie improves patient health through better adherence and self-management while enabling doctors to be paid for remote work and saving costs across health systems by avoiding hospital admissions. Adherium's clinically proven sensors, app and powerful data platform provide remote, real-time, personalised information to patients and clinicians. Adherium is increasing sales in US and other markets by pursuing partnerships with major hospital systems, medical groups and insurers. For more information, visit <https://www.adherium.com/>.



About the Hailie Platform

Adherium's proprietary Hailie® platform is transforming the management of chronic respiratory conditions including asthma and chronic obstructive pulmonary disease. Hailie's cloud-based platform captures and shares information from Bluetooth enabled sensors that wrap around a patient's prescribed inhaler. With a user-friendly app, a patient can receive, act on and share their personal information and data reports with doctors and carers.

Hailie's growing portfolio of sensors have been cleared by the FDA and approved by the TGA, EU and UK. The clinically proven sensors remotely capture when and how an inhaler is being used through key physiological parameters including inhalation flow rate, anywhere people live, work and study.

The Hailie solution creates and delivers data supporting far better patient medication adherence, behavioural influencing, escalations and interventions to improve health outcomes and self-management by patients. The Hailie platform drives health costs down by reducing hospital admissions and enables doctors to bill for remote patient management.

Independent studies show the Hailie platform increases medication adherence by 180% in children with an associated 80% reduction in hospital admissions. Hailie has been shown to increase adherence by 59% in adults with a reduction in severe exacerbations of 61%.